VREX — Varex Imaging Corporation

Is VREX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Oversold As of November 17, 2026

Varex Imaging Corporation (VREX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $18.10. The rating moved from Neutral to Oversold on November 12, 2026.

See all oversold Healthcare stocks →

AI analysis

Varex Imaging Corporation (VREX) is well positioned as a specialist supplier of X‑ray and imaging components benefiting from secular growth in diagnostic and intraoperative imaging and the incremental demand driven by broader adoption of robotic and minimally invasive procedures. The business combines recurring replacement/consumable revenue with exposure to OEM capex cycles, creating upside if hospital budgets and elective procedure volumes remain steady or improve. Key catalysts include renewed OEM ordering, product mix shift to higher‑margin components, and potential tuck‑in M&A, while primary risks are capital‑spending cyclicality, customer concentration, supply‑chain pressures, and reimbursement/regulatory headwinds. Near term performance will track order flow, backlog conversion, and any signs of margin recovery.

Key factors

  • Leading position in X‑ray imaging components and subsystems with recurring consumable and replacement revenue streams
  • Favorable secular demand drivers for diagnostic and intraoperative imaging (aging population, increased imaging utilization, expansion of minimally invasive and robotic surgery)
  • Exposure to OEM capital spending cycles that can reaccelerate with improving hospital budgets and elective procedure volumes
  • Potential upside from distributor and channel shifts toward specialty care and biopharma services increasing demand for specialized imaging solutions
  • Operational leverage: margin recovery possible from mix shift to higher‑margin components and ongoing cost control initiatives
  • M&A optionality and integration of acquired franchises could add product breadth and cross‑sell opportunities

Risks

  • High cyclicality tied to hospital and OEM capital expenditures that can compress revenue and backlog during macro slowdowns
  • Concentration risk with a limited number of large imaging OEM customers; loss or order delays from a major customer would materially impact revenue
  • Supply‑chain and component cost pressures (semiconductors, specialized parts) that can squeeze margins or lengthen lead times
  • Reimbursement pressure and healthcare regulatory changes that could reduce procedure volumes or delay capital procurements
  • Competition from larger diversified medtech suppliers and vertical integration by OEMs producing their own components
  • Foreign‑exchange and geopolitical exposure in key manufacturing or end‑market regions could disrupt sales or increase costs
  • Execution risk on any integration or product development initiatives and the potential for quality/regulatory issues with imaging components

See today's live rating, score and targets

Members see the live hourly rating for VREX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.